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Nucleoside analogues are first line chemotherapy in various severe diseases: AIDS (ac-
quired immunodeficiency disease syndrome), cytomegalovirus infections, cancer, etc.
However, many nucleoside analogues exhibit poor oral bioavailability because of their high
polarity and low intestinal permeability. In order to get around this drawback, prodrugs
have been utilized to improve lipophilicity by chemical modification of the parent drug.
Alternatively, prodrugs targeting transporters present in the intestine have been applied to
promote the transport of the nucleoside analogues. Valacyclovir and valganciclovir are two
classic valine ester prodrugs transported by oligopeptide transporter 1. The ideal prodrug
achieves delivery of a parent drug by attaching a non-toxic moiety that is stable during
transport, but is readily degraded to the parent drug once at the target. This article presents
advances of prodrug approaches for enhancing oral absorption of nucleoside analogues.
ª 2014 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction
Nucleoside analogues are synthetic compounds that are struc-
turally similar to natural nucleosides and, as such, are building
blocks of nucleic acids. They act either as inhibitors of cellularHospital of China Medic
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mode action [1]. Currently, nucleoside analogues are supposed
to be drugs that are given in first attention in many serious
diseasessuchasacquired immunodeficiencydisease syndrome
(AIDS), hepatitis, cancer, herpes, smallpox, etc [2]. Of the
approximately 40antiviral drugs formally approved foruse,half
are nucleoside or nucleotide analogues [3]. Nucleoside drugs
usually must be phosphorylated to the corresponding tri-
phosphates by intracellular or viral kinases [4] in order to exert
their pharmacological activity.
Transport of nucleoside analogues across the gastrointes-
tinal tract is often mediated by passive diffusion or active
transporters (Naþ-independent equilibrative transporters and
Naþ-dependent concentrative transporters) [1]. However,
their physicochemical properties are unsuitable for passive
transcellular intestinal absorption. Meanwhile, nucleoside
analogues are not natural substrates and show low affinity for
nucleoside transporters. Hence, oral absorption of nucleoside
analogues is often limited [5].
Variety of nucleoside analogues such as ganciclovir (GCV;
marketed Cimevan and Virgan) (used for the treatment of
cytomegalovirus retinitis) or cidofovir (CDV; marketed as
Vistide) [6,7] are, however, not bioavailable after oral
administration. Others like the anti-HIV nucleosides,
although orally bioavailable, suffer from unfavourable phar-
macokinetics [8e11] that necessitates the frequent oral
administration to maintain therapeutical plasma level in
human, also resulting in serious side effects such as bone
marrow suppression (anaemia and neutropenia) [12],
pancreatitis and peripheral neuropathy [13].
Since the polarity entails nucleosides with low perme-
ability and bioavailability, increasing efforts in the literature
are focussing on overcoming these difficulties with nucleotide
prodrugs, an approach which improves the lipophicity and
eventually releases the parent nucleotide at a specific site. In a
nucleotide prodrug, nucleoside analogues are usually cova-
lently bonded to the carrier molecule via phosphoester bond,
carboxylic ester bond, carbamate bond or amide bond. The
sensitivity of these chemical bonds to enzymatic or chemical
hydrolysis has a significant impact on the potency of nucleo-
tide prodrugs. The article highlights the progresses of oral
prodrug approaches for nucleoside analogues over the last
two decades. Within this review, we have discussed several
carboxylic ester prodrugs, monophosphate prodrugs and
other prodrugs, with a special focus on rational prodrug
design and their performances. It aims to provide some evi-
dences for rational design of oral nucleotide prodrugs.2. Prodrugs of nucleoside analogues
2.1. Carboxylicacidesters prodrugs
Carboxylicacidesters prodrug approach is widely used to
improve oral absorption of nucleoside analogues, in which the
hydroxyl group located at the side chain of nucleoside ana-
logues is esterified with organic acid and vice versa. The
carboxylicacidesters-type prodrugs usually possess signifi-
cant enhancement in water-solubility, cell membrane
permeability, enzyme stability and bioavailability, etc.2.1.1. Acyclovir and its prodrugs
Acyclovir (ACV) belongs to BCS III class drugs and possesses
activity against human herpes viruses. However, owing to its
limited bioavailability (20%), ACV shows moderate antiviral
efficacy after oral administration. Hence, it is necessary and
feasible to design a prodrug for improving oral absorption of
ACV.
Valacyclovir (VACV) is the valine ester prodrug of ACV
targeting intestinal oligopeptide transporter 1 (PepT1) and has
been proved to be safe and effective drug (Fig. 1). It has been
the most successful prodrug targeting PepT1. PepT1 is a
proton-coupled transporting protein and predominantly
distributed in the small intestinal epithelial cells. It has
become a striking prodrug-designing target recently, since
some poorly absorbed drugs can be modified as peptidomi-
metic prodrugs targeting intestinal PepT1 to improve oral
absorption of the parent drug. 30-hydroxyl group of ACV was
esterified with L-valine to prepare VACV. VACV has been re-
ported to increase the oral bioavailability of ACV by 3- to 5-fold
in humans. The Cmax values was increased significantly from
2.5 mM to 12.0 mM as well as the AUC0-t values from 19.7 mM$h
to 49.7 mM$h [14,15]. Enhanced oral absorption of ACV has
been attributed to the hPepT1-mediated intestinal membrane
translocation of prodrug VACV [16,17]. Recently, the enzyme
responsible for hydrolytic activity toward VACV (hVACVase)
has been identified and purified from Caco-2 cells. The high
expression of hVACVase in the human intestine, kidney, and
liver suggest an important role for hVACVase in the bio-
activation of VACV in human tissues [18,19]. The peptide
transport pathwaywas supposed to bemore efficient than the
amino acid transport system [20]. Therefore, several novel
water-soluble dipeptide ester prodrugs of ACV were devel-
oped for improving ocular and oral absorption of ACV via
targeting the peptide transporters [21]. The enzymatic stabil-
ity and permeability of GVACV (Fig. 1) (t1/2 ¼ 108.1  2.4 min,
Papp ¼ 2.99  0.59  106 cm/s) was comparable with that of
VACV (t1/2 ¼ 123.7  8.3 min, Papp ¼ 3.01  0.21  106 cm/s)
[22]. Interestingly, the oral bioavailability of ACV for GVACV
(AUC0et ¼ 416.1  140.9 mg$min/ml) was approximately 2-fold
higher than VACV (AUC0et ¼ 208.4  41.2 mg$min/ml), which
may result from its higher enzymatic stability in Caco-2 cell
homogenates than VACV [23]. Moreover, there was extensive
metabolism by hepatic first pass-effect of the dipeptide pro-
drugs as evidenced by the higher levels of ACV observed in the
portal vein than in jugular vein.
After the successful attempt of PepT1-targeted prodrug
approach, the dipeptidylpeptidase IV (DPPIV/CD26) prodrug
strategywas applied to ACV for improvedwater-solubility and
oral bioavailability. DPPIV/CD26 belongs to a unique class of
membrane-associated peptidases [24]. It is widely distributed
on variety of cell membranes, such as various leucocyte cell
subsets and several types of epithelial, endothelial, and
fibroblast cells. Furthermore, a soluble formof the enzymehas
been detected in cerebrospinal fluid and plasma at low
amounts [25,26]. Depending on the site of attachment of the
peptide promoiety, both peptidyl amide and ester prodrugs of
ACV were prepared. The tetrapeptide amide prodrug 3 (Fig. 3)
and the tripeptide ester prodrug 4 (Fig. 1) improved the water-
solubility more than 17-fold and 9-fold, respectively,
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prodrug of ACV, both the prodrugs were fully stable in PBS.
Meanwhile, they could convert to VACV (for 4) or ACV (for 3)
upon exposure to purified DPPIV/CD26 or human or bovine
serum [27]. This result indicates that the DPPIV/CD26 prodrug
approach could be useful for increasing the water-solubility of
polar drugs and possibly oral absorption.
2.1.2. Ganciclovir and valganciclovir
Ganciclovir is an acyclic guanosine analogue, which was first
used intravenously to treat CMV infection in AIDS patients. Tocircumvent the inconvenience and risks associated with
frequent intravenous administration, an oral formulation has
been further developed, because of its low bioavailability
(approximately 5%) [28].
Based on the model exemplified by valacyclovir, valganci-
clovir, an L-valyl-ester prodrug of ganciclovir (Fig. 1), has been
synthesized. The bioavailability of orally administered val-
ganciclovir rose up to 61%, almost 10 times higher than the
parent drug [29]. Consequently, once-daily oral administra-
tion of 900 mg of valganciclovir was as effective as once-daily
intravenous injection of 5 mg/kg of ganciclovir [30].
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Didanosine (50-O-20-30-dideoxydidanosine, DDI) is the second
anti-HIV drug approved by the FDA, which is well tolerated
with chronic administration with rare and usually reversible
toxicity [31]. However, DDI exhibits poor bioavailability
(20e40%) [1], which necessitates the continuous infusion to
maintain therapeutical plasma level in human. Many in-
vestigations had focused on the development of DDI prodrugs
for improved oral absorption, but none of them were in
routine clinical use [32e34]. Yan et al synthesized five pepti-
domimetic derivatives of DDI targeting PePT1. The 50-O-L-valyl
ester prodrug of DDI (50-O-L-valyl-DDI) (Fig. 1) demonstrated
the highest permeability in Caco-2 cell model and was
selected as the optimal candidate for further studies. The oralFig. 3 e Amide-type prodrugs discussed in this review.absolute bioavailability of DDI was improved from 7.9% to
47.2% after 50-valyl prodrug orally administered to rats at a
dose of 15 mg/kg. It was reported that the prodrug could
markedly improve DDI acidic stability in SGF, with the t1/2 to
be 36 min in SGF, while the parent drug could not be detected
in the 2 min. The enhanced acidic stability was confirmed
again by the coadministration with anti-acid agent in the
in vivo oral pharmacokinetics. Antacid combination of DDI
increased the oral bioavailability by 115.8%, while 50-O-L-
valyl-DDI (antacid combination) only increased by 30.1% [35].
2.1.4. Penciclovir and famciclovir
Penciclovir is an acyclic guanosine nucleoside analogues,
which displays a similar spectrum of selectivity and antiviralThe red numbers parts represent the parent drugs.
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bioavailability (F<7%) [37], it is necessary to design an oral
alternative of penciclovir. Famciclovir (Fig. 1) is a double pro-
drug containing acetyl diester and 6-deoxy promoieties. It can
be efficiently bioactived to the parent drug via enzymatic
deacetylation and oxidation after oral administration [38,39].
Famciclovir has been proved to be effective for human genital
herpes infections and herpes zoster [40]. Clinical studies
demonstrated the prodrug could be rapidly absorbed and the
oral bioavailability of penciclovir rose up to 77% following a
single dose of famciclovir [41]. In contrast, the acetyl diester of
penciclovir did not show any enhancement in oral absorption
compared to the parent drug [37]. Monocarbonate prodrugs of
6-deoxy penciclovir were also assessed in vivo with the hope
of more efficiently converting the prodrug to the parent form.
Slightly higher or comparable urinary recovery of penciclovir
was observed with several monocarbonate prodrugs in mice
and rats compared to famciclovir [42].
2.1.5. b-D-20-Deoxy-20-fluoro-20-C-methylcytidine and
RG7128
b-D-20-Deoxy-20-fluoro-20-C-methylcytidine (PSI-6130), a
potent inhibitor of HCV replication in Huh7 replicon assay,
exhibits broad activity against HCV without obvious cytotox-
icity [43]. It entered into clinical trials but showed onlymodest
oral absorption and it was easily degraded to inactive uridine
metabolite. In order to get around this drawback, Furman et al
prepared a series of bis-isobutyryl ester prodrugs of PSI- 6130.
It was reported that RG7128 (mericitabine; Fig. 1) was themost
advanced, simple nucleoside prodrug in clinical trials [44].
During Phase I study, RG7128 has shown efficacy when
applied in patients infected with HCV genotypes 1, 2 and 3.
RG7128 entered into Phase IIb clinical trials. Early reported
data (a 12-week analysis) suggest an average 83% of complete
early virological response for the 1000 mg b.i.d./SOC cohort
[45]. RG7128 is expected to enter themarket in the near future.
2.1.6. Cf1743 and its prodrugs
Bicyclic furanopyrimidine nucleoside analogues (BCNAs), a
family of highly lipophilic antivirals, display high inhibitory
potency and unusual selectivity against varicella zoster virus
(VZV) [46]. The most potent anti-VZV prototype compound is
the p-pentylphenyl BCNA analogue Cf1743, which displays
activity against a broad range of VZV isolates at nanomolar
concentrations and little or no detectable toxicity at micro-
molar concentrations [47]. However, the very poor aqueous
solubility of Cf1743 gives low oral bioavailability (w14%) [48].
Formulation-based strategies were successful in enhancing
the water-solubility of Cf1743 but did not have a remarkable
impact on oral absorption [48]. To solve this problem, Alberto
et al synthesized a series of prodrugs of Cf1743 (Fig. 1) tar-
geting DPPIV/CD26. Alberto et al demonstrated the prodrugs
efficiently released the parent BCNA drug upon selective
conversion by purified DPPIV/CD26 and by soluble DPPIV/
CD26 present in bovine, murine, and human serum. Addi-
tionally, the hydrolysis of the prodrugs in the presence of
purified DPPIV/CD26, human, murine, and bovine serum was
completely blocked, when treating with 2.5 mM vildagliptin (a
specific inhibitor of DPPIV/CD26). Among the DPPIV/CD26-
targeted prodrugs, several prodrugs showed significantincrease in water-solubility (up to more than 1000-fold)
compared to the poorly soluble parent drug. Those prodrugs
have been reported to increase the oral bioavailability of
Cf1743 by 7- to 5-fold in mice [49].
2.1.7. 30-Fluoro e 20, 30-dideoxyguanosine and its
valyloxypropyl ester prodrug
GlaxoSmithKline Company developed 30-fluoro-20, 30-dideox-
yguanosine, which displays activity against HBV. It is phos-
phorylated by deoxycytidine kinase in vivo to form an active
metabolite, 30-fluoro-20, 30-dideoxyguanosine triphosphate.
This analogue is then incorporated into DNA and prevents
DNA reproduction of virus. However, it exhibits low oral
bioavailability (only 10% w 20%). Hence, its 50-O-(S)-2-L-valy-
loxypropyl ester prodrug (Fig. 1) was synthesized to improve
oral absorption of 30-fluoro-20, 30-dideoxyguanosine. It was
reported the oral bioavailability rose up to 50% [50].
2.2. Monophosphate prodrugs
For exerting antiviral activity, the majority of the nucleoside
analogues are required to be phosphorylated by a kinase
in vivo to form corresponding active metabolites, tri-
phosphates. Since the rate-limiting step in the formation of
triphosphate is conversion of nucleoside analogue to its
monophosphate, monophosphate ester prodrugs of nucleo-
side analogues were designed in an attempt to circumvent the
initial phosphorylation activation step. Acyclic nucleoside
phosphonate (ANP) is a new class of antiviral agents, which
does not need initial phosphorylation by viral nucleoside ki-
nases to exert their antiviral effect. Instead, the drugs undergo
two phosphorylation reactions to their active forms by cellular
enzymes [51]. Consequently, unlike other nucleoside ana-
logues, ANP analogues do not readily lead to virus drug
resistance.
However, owing to poor intestinal membrane permeability
of the charged molecules, many phosphate prodrugs are not
suitable for oral absorption. Hence, prodrug derivatives to
mask the ionized phosphate group of nucleosides have been
exploited [52,53], but the strategy can be limited because of
rapid hydrolysis of the phosphate esters in vivo. However, the
problem can be resolved by attaching the phosphonate group
to acyclic nucleosidemoiety through a stable PeC bond, which
is resistant to esterase hydrolysis. Prodrugs of the acyclic
nucleoside phosphonates (ANP) can mask the negative
charges on the phosphonate groups and thus improve cellular
permeability.
2.2.1. Adefovir and its prodrugs
Adefovir is an acyclic analogues of deoxyadenosine and it
displays low oral bioavailability as other ANP analogues due to
limited intestinal permeability of the anionic phosphonate
moiety [54,55]. Hence, various prodrugs of adefovir were
designed to mask the charged phosphonate groups and
improve oral absorption of adefovir.
It was reported that simple alkyl di-esters or amides pro-
drugs of adefovir failed to efficiently convert to adefovir in vivo
[56]. Additionally,monoesters showed poor oral bioavailability
probably because of the unmasked ionized phosphate groups.
In this situation, a bis(pivaloyloxymethyl) ester prodrug of
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 9 ( 2 0 1 4 ) 6 5e7 470adefovir (adefovir dipivoxil) (Fig. 2) was prepared. The prodrug
possesses increased lipophilicity and greater intestinal
permeability than adefovir. Furthermore, it is rapidly con-
verted to the parent drug in vivo and leads to observably higher
oral absorption. According to the published data, the oral
bioavailability of adefovir dipivoxil in humans roseup to 3- and
3.8-fold of free adefovir at dose of 125e500mg [57,58]. Another
study with a dose of 10 mg adefovir dipivoxil showed approxi-
mately 4-fold increase of oral bioavailability of adefovir [59].
Adefovir dipivoxil is currently licensed for a standard treat-
ment for chronic hepatitis B, particularly in patients with a
lamivudine-resistant HBV infection.
2.2.2. Cidofovir and its prodrugs
Cidofovir (HPMPC), an acyclic nucleoside phosphonate, is a
potent and selective inhibitor of viral DNA synthesis licensed
for the treatment of cytomegalovirus retinitis in AIDS patients
[60]. Cidofovir itself is a prodrug, which should be transformed
to activated triphosphate in vivo. However, due to its polarity
of the phosphate group and limited intestinal membrane
permeability, HPMPC exhibits low oral bioavailability of <5%
and it must be administered by intravenous infusion [7,54].
Meanwhile, cidofovir displays dose-limiting nephrotoxicity
due to high concentration in the kidney, which promotes the
development of safe cyclic analogue of cidofovir. Cyclic cido-
fovir (Fig. 2) is chemically stable and it can be converted to
cidofovir in vivo by a cellular cyclic CMP phosphodiesterase.
Compared to intravenous cidofovir, the prodrug has similar
antiviral activity but lower potential for nephrotoxicity in
humans [61]. The oral bioavailability of cyclic cidofovir is also
limited, because it can only be absorbed through cell pinocy-
tosis in the gut. To improve oral bioavailability of cidofovir and
cyclic cidofovir, ether lipid ester prodrugs were synthesized.
These prodrugs were designed to use the lysophosphati-
dylcholine (LPC) uptake pathway in the small intestine and
achieve high oral availability. Esterification of the phospho-
nate with several alkyoxyalkanols showed remarkable
improvement in oral bioavailability in mice (88e97%) [62e64].
The lipid prodrugs were absorbed intact and converted slowly
to the parent drug in tissues. Enhanced antiviral activities of
these prodrugs were observed both in vitro and in vivo [65,66].
The improvement in activity was attributed to the increased
cellular uptake of cidofovir and intracellular levels of cidofovir
diphosphate [67]. After that attempt, another prodrug Val-Ser-
cyclic HPMPC was synthesized by Amidon group, which was a
promising peptide prodrug targeting puromycin-sensitive
aminopeptidase and had been shown to improve the perme-
ability and bioavailability of HPMPC in rodent models. The
prodrug was initially activated by puromycin-sensitive
aminopeptidase to remove the L-valine residue. Subsequent
chemical hydrolysis resulted in the generation of cyclic
HPMPC [68,69].
2.2.3. Tenofovir and its prodrugs
Tenofovir is structurally similar to adefovir with an extra
methyl side chain. As other ANP analogues, poor oral
bioavailability of tenofovir (10%) was anticipated in humans.
Hence, prodrugs were developed for enhanced oral delivery.
Previous clinical experience with adefovir dipivoxil showed
that pivalic acid discharged from the prodrug formedconjugates with carnitine leading to decreased serum carni-
tine levels [58]. To solve this problem, a series of prodrugswith
alkoxycarbonyloxymethyl groups was designed but with a
weak absorption because of hydrolysis before trans-
membrane. Meanwhile, carbamate prodrugs also failed to
improve bioavailability of tenofovir, probably because of their
high enzymatic stability [70]. Based on stability, solubility, and
enhanced oral absorption (1.5-fold of tenofovir in dogs),
bis(isopropyloxycarbonyloxymethyl) ester of tenofovir (teno-
fovir disoproxil) (Fig. 2) was chosen for further study [55,71].
Furthermore, Caco-2 cell transport of the prodrug was
increased from 0.1% to 2.7% [55]. The oral bioavailability of
tenofovir was 25% after oral administration of tenofovir dis-
oproxil fumarate at dose of 300 mg in human and rose up to
39% with food [72]. Moreover, tenofovir disoproxil fumarate
showed a broad spectrum of antibacterial activities compared
to the parent drug and could be applied for the treatment of
drug-resistant HIV and HBV infections.
2.2.4. Abacavir and its prodrugs
McGuigan has investigated a series of pronucleotides such as
alkyloxy phosphoramidates, phosphorodiamidates, diaryl
triesters and aryloxy phosphoramidates. However, the ary-
loxy phosphoramidates (‘ProTides’) were proved to be the
most successful pronucleotides, in which an amino acid ester
promoiety was attached to the drug (as an aryl mono-
phosphate or phosphonate) via a PeN bond. The ProTides
approach has been applied to many nucleoside analogues,
such as 30-azidothymidine [73], abacavir [74] and tenofovir
[75]. However, it is difficult to obtain optimal antiviral activity
of each pronucleotide, the fine-tuning of each element (amino
acid, ester, and aryl moiety) is required.
Aryloxy phosphoramidates were expected to release the
nucleoside monophosphate intracellularly via both chemical
and enzymatic mechanisms. The first step is cleavage of the
amino acid ester by a carboxyesterase. Subsequently, nucle-
ophilic attack at the phosphorus by the carboxyl group re-
leases the aryloxy group, forming the amino acyl metabolite
(AAM). Finally, the amino acid moiety is removed by a phos-
phoramidase to release the nucleoside monophosphate and
an amino acid [76].
The pharmacokinetics and oral bioavailability of abacavir
phosphoramidates (Fig. 2) were investigated [77]. It was found
that the pronucleotide was rapidly converted to AAM with a
half-life of several minutes, after oral administration of the
abacavir methylalaninyl-phosphoramidate. Total exposure to
the pronucleotide and its active metabolites was reported to
approach that estimated for abacavir at a similar dose,
resulting in an overall bioavailability of 50%.
2.3. Amide-type prodrugs
2.3.1. Gemcitabine and its prodrugs
Nucleoside analogues are usually poorly active after oral
administration, because of their limited intestinal perme-
ability and rapid metabolism to inactive metabolite in the gut
or due to their high first pass metabolism. For example,
Gemcitabine (dFdC) is an important anticancer drug that has
been licensed for the treatment of non-small cell lung, breast
cancer and pancreatic bladder [78]. Gemcitabine is extensively
a s i a n j o u rn a l o f p h a rm a c e u t i c a l s c i e n c e s 9 ( 2 0 1 4 ) 6 5e7 4 71metabolized to 20,20-difluoro-20-deoxyuridine (dFdU) by cyti-
dine deaminase [79] which abound in blood, liver and gut. This
has limited dFdC use to the parenteral route in clinical.
Therefore, several oral prodrugs of gemcitabine were
designed by coupling acyl chains covalently to the 4-amino
group of gemcitabine, in which the 4-amino group was
modified with fatty acids [80] or acyclic isoprenoid chain of
squalene (GemSq) [81] (Fig. 3). These lipophilic derivatives of
gemcitabine were found to have a slower metabolism in
plasma and higher cytotoxicity than gemcitabine. Due to their
lipophilicity, these derivatives are also expected to have an
increased oral bioavailability compared to gemcitabine. This
latest strategy (enhancing lipophilicity) undergoes further
development.
LY2334737 is another amide prodrug of gemcitabine (val-
proic acyl prodrug). Early preclinical studies have shown that
LY2334737 is more stable to hydrolysis and leads to enhanced
bioavailability by blocking the site of deamination to its uri-
dinemetabolite. This can lead to prolonged systemic exposure
of gemcitabine compared to both IV and oral administration of
gemcitabine. Subsequent pharmacokinetic study proved that
the prodrug was absorbed mostly intact across the intestinal
membrane and then delivered to systemic circulation. The
hydrolysis of LY2334737 was relatively slow, leading to sus-
tained release of gemcitabine in vivo [82]. Phase I study of oral
LY2334737 in Japanese patients with advanced solid tumours
demonstrated LY2334737 was tolerated by Japanese patients
up to 30 mg/day. The toxicities observed at the 40 mg dose
may require the development of alternative dosing schedules
[83].
2.3.2. Carbovir and abacavir
Carbovir is a carbocyclic nucleoside analogue with anti-HIV
activity. It was abolished as a drug candidate because of poor
oral absorption in rats (26%) and monkeys (23%), poor brain
penetration, and kidney and cardiac toxicities [84]. Abacavir
(Fig. 3) was a 6-modified carbovir analogues, which is more
lipophilic than carbovir with a log P value of 1.22 for abacavir
versus 0.62 for carbovir, leading to higher CNS penetration
and oral bioavailability (76e100% in animals and 83% in
human) [85]. After oral administration, abacavir is first phos-
phorylated to abacavir monophosphate in vivo by adenosine
phosphotransferase and then converted to carbovir mono-
phosphate by a cytosolic deaminase, finally transformed to
carbovir triphosphate [86]. The unique activation pathway
enabled abacavir to overcome the deficiencies of carbovir.
2.3.3. Ribavirin and viramidine
Viramidine (Fig. 3), a liver-targeting amidine prodrug of riba-
virin, is designed to circumvent haemolytic anaemia caused
by the parent drug.
Probably due to the positive charge on viramidinemolecule,
the uptake of viramidine in red blood cells is less than riba-
virin, eventually resulting in a reduction in haematological
toxicity [87]. The oral bioavailability of viramidine was 66.1%,
43.9% and 61.7% in human, monkey and rat, respectively
[88,89]. Viramidine is activated to ribavirin in the liver by
adenosine deaminase and exhibited a higher liver-to-
erythrocyte drug ratio, which suggesting better liver-target-
ing properties. Furthermore, both preclinical and clinicalstudies showed superior safety profiles of viramidine
compared to the parent drug [90,91]. Currently, the prodrug
entered in Phase III studies in patients with chronic hepatitis C
infection.3. Conclusion
Nucleotide analogues play an essential role in the treatment of
cancer and viruses. Since the rate-limiting step in the forma-
tion of triphosphate is conversion of nucleoside analogues to
its monophosphate, monophosphate ester prodrugs of nucle-
oside analogues were designed in an attempt to circumvent
the initial phosphorylation activation step. However, both
nucleoside analogues and monophosphate ester prodrugs of
nucleoside analogues are polar molecules and have limited
membrane permeability. Hence, traverse of intestinal epithe-
lial membrane is often limited. Over the past decade, several
creative prodrug strategies have been utilized to overcome
these limitations. The examples described in this review
illustrate the significant research efforts done to improve the
oral bioavailability of nucleoside analogues. Traditional pro-
drug approaches by enhancing lipophilicity have been applied
to improve passive diffusion. Prodrugs targeted to PepT1 have
been found very useful for enhancing oral absorption of polar
drugs. PepT1 has become a promising target since they are
highly expressed in the intestine with high capacity and
diverse substrate specificity. Advances in prodrug design have
improved the value of nucleoside compounds as anticancer
and antiviral agents. The examples described in this article
further prove that prodrug approach is an effective strategy for
improving oral absorption of nucleoside analogues.
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